Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently) accounting for ~60–80% of cases.
The exact cause of Alzheimer's disease is unknown, although a number of things are thought to increase risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer's is difficulty in remembering newly learned information because Alzheimer's changes typically begin in that part of the brain that affects learning.
According to Alzheimer’s Association, more women than men have Alzheimer’s or other dementias. It is suspected that Alzheimer's disease starts 20 years or more before signs appear, with brain changes that are unnoticeable to the affected individual. Individuals suffer significant symptoms including memory loss and language difficulties only after years of brain changes.
Accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons are the characteristic pathologies of Alzheimer's disease. The death of neurons and damage to brain tissue are accompanied by these changes. By interfering with neuron-to-neuron contact at synapses, plaques and smaller accumulations of beta-amyloid called oligomers may lead to the damage and death of neurons (neuro-degeneration). The transport of nutrients and other important molecules within neurons is blocked by Tau tangles.
#DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers.
Some of the Companies are- Shanghai Green Valley Pharmaceuticals, Eisai Inc. etc
Have a Copy our Newsletter- https://www.delveinsight.com/whitepaper-newsletter/alzheimers-disease-newsletter
Know More About What's Covered:
· Indication overview
· Signs, symptoms, and diagnosis
· Epidemiological trends
· Treatment approaches
· Unmet needs
· Key Companies
· Market insights
· Clinical trials
· Pipeline drugs
· Collaborations and deals in the domain
· Top conferences
· R&D in the field
· Support from International organizations
Have a Copy our Newsletter- https://www.delveinsight.com/whitepaper-newsletter/alzheimers-disease-newsletter
#raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #Alzheimer’sdisease #readerscommunity #readinglist #newsletterdesign
Comments
Post a Comment